Table 2.

Results of in vivo efficacy of polymer-paclitaxel conjugates.

Mice/Rats	Bearing cancer cells	Treatment	Administration	Dose (mg/kg)	Efficacy	Toxicity	Ref.
Female BALB/c nude mice	Human lung H-460 cancer	PGG-PTX	a single i.p. dose	150	Significant antitumor activity in a well-defined dose-dependent manner.	Increased in toxicity as the doses increased	[22]
				200
				250
				300
	Human lung H-460 cancer	PGG-PTX	a single i.p dose	300	Significant inhibition of tumor relative to that in the control mice (P = 0.001) but not to that in the Abraxane treated mice (P = 0.92).	Both drugs produced equivalent acute reductions in body weight. Weight recovery more rapid with Abraxane.
		Abraxane		250
	Human 2008 ovarian carcinoma	PGG-PTX	a single i.p dose	300	Significant inhibition of tumor relative to that in the control mice (P = 0.006) and that in the Abraxane treated mice (P = 0.025).	Both drugs produced equivalent acute reductions in body weight. Weight recovery more rapid with Abraxane.
		Abraxane		200
Female BALB/c nude mice	Murine B16 melanoma	PGG-PTX	a single i.p dose	350	Significant inhibition of tumor relative to that in the control mice (P = 0.0002) and that in the Abraxane treated mice (P = 0.020).	Both drugs produced equivalent acute reductions in body weight. Weight recovery more rapid with Abraxane.	[22]
		Abraxane		150
	Human lung H-460 cancer	PGG-PTX	a single i.v. dose weekly for 3 weeks	140	Significant inhibition of tumor relative to that in the Abraxane treated mice (P = 0.020).	Mimimal weight loss with PGG- PTX but significant weight loss with Abraxane treatments.
		Abraxane		40
C3H/Kam mice	Murine ovarian OCA-1 carcinoma	PG-PTX	a single i.v. dose	80	Significant tumor growth delay at 80 mg/kg compared with paclitaxel. Tumor growth suppressed at 160 mg/kg. 25 of 26 mice remained tumor-free after 2 months.	No mice treated with PG-PTX died during the experimental period, whereas 2 of 13 mice treated with paclitaxel died.	[15]
				160
		Paclitaxel		80
Female Fischer 344 rats	Rat mammary 13762F adeno-carcinoma	PG-PTX	a single i.v. dose	20	Tumor suppression at 20 mg/kg of PG-PTX. Tumor regression at 40 mg/kg of PG-PTX.
				40
		Paclitaxel		40
C3H/Kam mice	Murine mammary MCa-4	PG-PTX	a single i.v. dose	60	Tumor regression at 120 mg/kg from days 8-19, but tumors reappeared on day 21, with slower rate compared with Taxol treated mice.		[20]
				120
		Paclitaxel		60
	Murine mammary MCa-35	PG-PTX	a single i.v. dose	80	Significant tumor growth delay at the MTD of 160 mg/kg paclitaxel.
				160
		Paclitaxel		80
C3H/Kam mice	Murine Hepatocellular HCa-1	PG-PTX	a single i.v. dose	80	Significant tumor growth delay at 160 mg/kg paclitaxel.	Mice treated with PG-PTX maintained their body weight; whereas mice treated with paclitaxel quickly lost weight.	[20]
				160
		Paclitaxel		80
	Murine soft-tissue Fsa-II sarcoma	PG-PTX	a single i.v. dose	80	Similar patterns of sensitivity to PG-PTX and paclitaxel.	Both PG-PTX and paclitaxel reduced body weight loss.
				160
		Paclitaxel		80
		PG-PTX	Three injections	120	Extended the survival time but no statistically significant difference compared with paclitaxel-treated mice at 100 days. No difference even with treatment of 3 injections.	20-30% survival at 100 days in paclitaxel-treated mice and PG-PTX-treated mice
Female BALB/c nude mice	Human ovarian SKOV3ip1 cancer	PG-PTX	a single i.v. dose	60
				120
		Paclitaxel		60
	Human breast MDA-MB-435Lung2 breast cancer	PG-PTX	Three injections	60	At 120 mg/kg, PG-PTX induced tumor regression in 50% of animals. Similar antitumor activity between multiple injections and a single injection.
		PG-PTX	A single i.v. injection	60
				120
		Paclitaxel		60